Shaily gets regulatory nod for launch of ShailyPen Neo device technology

The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity

Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

Nearly one in five women worldwide are now living with obesity

NIH-funded study uncovers hidden brain circuit behind GLP-1 weight-loss drugs

In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

OBESITAS 2026 concludes with focus on India’s rising obesity burden

The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges

NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures

Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens

The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c